PAS 003
Alternative Names: Alpha-5 - Pasithea Therapeutics; PAS-003Latest Information Update: 28 Jul 2026
At a glance
- Originator Alpha-5 Integrin
- Developer Pasithea Therapeutics
- Class Monoclonal antibodies; Neuroprotectants
- Mechanism of Action Integrin alpha5beta1 inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Amyotrophic lateral sclerosis; Neurological disorders
Most Recent Events
- 28 Jul 2026 No recent reports of development identified for preclinical development in Amyotrophic-lateral-sclerosis in USA (Intraperitoneal, Injection)
- 28 Jul 2026 No recent reports of development identified for preclinical development in Neurological-disorders in USA (Parenteral, Injection)
- 11 Aug 2025 PAS 003 is available for licensing as of 11 Aug 2025. https://www.pasithea.com/pipeline/